Abbott (NYSE:ABT) announced today that it is introducing the Libre Sense glucose sport biosensor for measuring athletes’ glucose. The company touts the Libre Sense as the world’s first glucose sport biosensor, using Abbott’s FreeStyle Libre continuous glucose monitor (CGM) technology to become the first personal-use product that allows for use beyond diabetes, according to a news […]
The top 5 MassDevice stories of the week — September 4, 2020
Medtronic (NYSE:MDT) and a major development involving medtech reimbursement dominated medical device industry news over the past week. As the week closes out, there’s also a trending story on MassDevice that includes good news: Abbott (NYSE:ABT) is reportedly hiring 2,000 new employees in Illinois to increase manufacturing for its rapid COVID-19 test. Want to hear more about […]
Abbott wins Medicare reimbursement for FreeStyle Libre 2
Abbott (NYSE:ABT) announced today that its next-generation FreeStyle Libre 2 iCGM is now available to Medicare patients. The integrated continuous glucose monitoring (iCGM) system met the codes for therapeutic CGM systems used for coverage by the U.S. Centers for Medicare & Medicaid Services (CMS), making it accessible to all Medicare patients with diabetes who meet the […]
FDA approves Medtronic MiniMed 770G insulin pump for young children
The FDA has approved the Medtronic (NYSE:MDT) MiniMed 770G hybrid closed loop-diabetes management system for Type 1 diabetes patients aged 2 to 6 years. The MiniMed 770G is the first-of-its-kind system that can automatically adjust insulin delivery based on continuous glucose monitor values for such young children, according to the agency. The FDA approved an earlier MiniMed […]
IBM uncovers software vulnerability that could affect insulin pumps
A team of IBM security researchers uncovered a potential vulnerability in software from Thales that could affect insulin pumps. IBM’s “X-Force Red” team discovered the internet of things (IoT) vulnerability that can be remotely exploited in September 2019 with Thales’ Cinterion EHS8 M2M module, according to a report from SecurityIntelligence. The software is used in […]
DTW Podcast: Can Fractyl Labs and Cala Health go where only drugs have gone before?
In this week’s DeviceTalks Weekly podcast, co-costs Tom Salemi and Chris Newmarker walk through this week’s “Newmarker’s Newsmakers,” the Top Five #medtech stories of the week with news coming from CureVac, Avail Medsystems, ClearMask, Thermo Fisher and Bayer. We also hear from CEO Harith Rajagopalan, MD and CFO Lisa Davidson of Fractyl Laboratories, which is […]
GI Windows raises $16.4M
Anastomoses technology developer GI Windows Medical announced that it raised $16.4 million in a Series A-1 financing round. West Bridgewater, Mass.-based GI Windows said in a news release that Johnson &. Johnson Innovation, Sonder Capital, GT Healthcare, JC Investco and an additional strategic investor contributed to the funding round. In addition to the institutional financing, […]
Medtronic to acquire Companion Medical, expands diabetes business
Medtronic (NYSE:MDT) today said it would acquire insulin pen manufacturer Companion Medical for an undisclosed amount. Companion Medical’s product portfolio includes the InPen FDA-cleared smart insulin pen system that is paired with an integrated diabetes management app on the market. It is designed to help calculate insulin doses, track active insulin and send reports to caregivers […]
Senseonics posts mixed bag Q2, partners with Ascensia
Senseonics (NYSE:SENS) shares rose slightly today on second-quarter results that were mixed compared to the consensus forecast. The Germantown, Md.-based implantable continuous glucose monitor maker also announced a deal with Ascensia Diabetes Care for global commercialization and distribution with concurrent financing worth up to $50 million. Senseonics posted losses of -$7.5 million, or -3¢ per share, […]
Fractyl adds $55M Series E for Type 2 diabetes pivotal trial
Fractyl Laboratories secured $55 million for a Series E financing to continue funding a pivotal clinical trial of its potential non-drug, non-surgical treatment for Type 2 diabetes, according to the company. The capital will go toward the Lexington, Mass-based start up’s Revita T2Di pivotal clinical trial of Revita DMR (duodenal mucosal resurfacing). Revita is measuring […]
Insulet up on Street-beating Q2, raised guidance
Insulet (NSDQ:PODD) shares ticked up today on second-quarter results that topped the consensus forecast. The Acton, Mass.-based wearable insulin delivery system developer posted profits of $14.4 million, or 22¢ per share, on sales of $226.3 million for the three months ended June 30, 2020, for a bottom-line gain of nearly ten times as much as last […]
- 1
- 2
- 3
- …
- 95
- Next Page »
